<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03854097</url>
  </required_header>
  <id_info>
    <org_study_id>1-014-18</org_study_id>
    <nct_id>NCT03854097</nct_id>
  </id_info>
  <brief_title>Effect of Intermittent Pressure in Patients With PAD</brief_title>
  <official_title>Mechanistic Insights Into Changes in Blood Flow Following Application of Intermittent Negative Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Dundee</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the effect of intermittent negative pressure (INP) on peripheral&#xD;
      arterial disease (PAD) patient vascular function and blood flow. Patients will be given&#xD;
      either -40mmHg INP or -10mmHg INP which will act as a placebo. Healthy volunteers will be&#xD;
      given -40mmHg INP to evaluate changes in vascular function and blood flow with INP in healthy&#xD;
      physiology.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atherosclerosis occurs when blood supply to the lower limbs is restricted upon accumulation&#xD;
      of fat in the arteries. Atheroslerosis in the lower limbs is termed peripheral arterial&#xD;
      disease (PAD). The initial symptom is pain in the lower limbs followed by ulceration and&#xD;
      gangrene. The literature has indicated that intermittent negative pressure (INP) can be used&#xD;
      to reduce pain and facilitate wound healing. INP is a non-invasive technique that aims to&#xD;
      increase arterial and skin blood flow in lower limbs and foot. This study aims to investigate&#xD;
      the underlying mechanisms that are involved in changes in blood flow following application of&#xD;
      INP. The Flow-Ox 'boot' will be used to apply INP for periods ranging from 4-8 weeks, for an&#xD;
      hour twice per day, to the lower limb to determine the effects of INP on vascular function&#xD;
      and blood flow. Specifically, vascular tests such as assessments of endothelial function,&#xD;
      arterial stiffness, ankle-brachial pressure index (ABPI) and blood borne metabolic and&#xD;
      inflammatory markers will be performed before and after INP application. A pain chart will be&#xD;
      employed before and after INP application to determine whether there is any change in&#xD;
      perception of pain felt by individuals who suffer from pain associated with lower limb&#xD;
      arterial disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 16, 2019</start_date>
  <completion_date type="Actual">June 5, 2021</completion_date>
  <primary_completion_date type="Actual">June 5, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in microvascular blood flow</measure>
    <time_frame>Baseline, 1 day and 4-8 weeks</time_frame>
    <description>Microvascular blood flow measurement in foot using laser Dopper imaging.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in microvascular endothelial function</measure>
    <time_frame>Baseline, 1 day and 4-8 weeks</time_frame>
    <description>Peak blood perfusion response to acetylcholine (ACh) delivered by iontophoresis will be measured using a laser Doppler imager.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in arterial stiffness</measure>
    <time_frame>Baseline, 1 day and 4-8 weeks</time_frame>
    <description>Brachial pulse wave analysis (PWA) augmentation index (Ax) and carotid-femoral pulse wave velocity (m/s) (PWV) as an indication of arterial stiffness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in macrovascular endothelial function</measure>
    <time_frame>Baseline, 1 day and 4-8 weeks</time_frame>
    <description>Brachial endothelial function measured as change in brachial blood vessel diameter (%) upon shear stress.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pain score</measure>
    <time_frame>Baseline, 1 day and 4-8 weeks</time_frame>
    <description>Self-scoring of pain felt by patient on a visual analogue scale with 0 being no pain at all to 10 being the worst pain ever felt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration of blood borne inflammatory and oxidative stress biomarkers</measure>
    <time_frame>Baseline, 1 day and 4-8 weeks</time_frame>
    <description>Concentration of inflammatory and oxidative stress markers of endothelial activation/damage (including IL-1a, IL-6, IL-10, TNF-a, CRP, E-selectin and sICAM-1) measured in serum and plasma collected from patient blood samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ankle-Brachial Pressure Index (ABPI)</measure>
    <time_frame>Baseline, 1 day and 4-8 weeks</time_frame>
    <description>Brachial systolic pressure and ankle (dorsalis pedis) systolic pressure (mmHg) measured using Doppler probe. ABPI calculated as ankle systolic pressure divided by brachial systolic pressure.&#xD;
ABPI &lt;0.9 = PAD, ABPI =&gt;1.0 Normal.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Active PAD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-40mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo PAD group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-10mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-40 mmHg of Intermittent Negative Pressure (INP) for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active Intermittent Negative Pressure (INP)</intervention_name>
    <description>Application of -40mmHg negative pressure on the lower limb</description>
    <arm_group_label>Active PAD group</arm_group_label>
    <arm_group_label>Healthy Volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo Intermittent Negative Pressure (INP)</intervention_name>
    <description>Application of -10mmHg negative pressure on the lower limb</description>
    <arm_group_label>Placebo PAD group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        PAD Patients:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Attending vascular outpatient clinics or admitted in ward with PAD.&#xD;
&#xD;
          -  ABPI &lt;0.9&#xD;
&#xD;
        Healthy Volunteers:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  No current or previous significant cardiovascular illness&#xD;
&#xD;
          -  Able to give written informed consent&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        PAD Patients:&#xD;
&#xD;
          -  Unable to give written informed consent&#xD;
&#xD;
          -  Patients with deep venous thrombosis&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
        Healthy Volunteers:&#xD;
&#xD;
          -  Positive medical history of: Vascular diseases such as PAD, stroke, IHD,&#xD;
             hypertension... etc.&#xD;
&#xD;
          -  Haematological conditions such as hypercoagulability, deep venous thrombosis... etc.,&#xD;
&#xD;
          -  Alcohol excess&#xD;
&#xD;
          -  Unable to give written informed consent&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jody McIntosh</last_name>
    <role>Principal Investigator</role>
    <affiliation>PhD student</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>School of Medicine, University of Dundee, Ninewells Hospital &amp; Medical School</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 19, 2019</study_first_submitted>
  <study_first_submitted_qc>February 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT03854097/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

